针对多种人类和动物冠状病毒感染的广谱抗病毒药物。
Broad-Spectrum Antivirals against Multiple Human and Animal Coronaviruses Infection.
作者信息
Saxena Divyasha, Batra Lalit, Verma Shailendra Kumar
机构信息
Center for Predictive Medicine, University of Louisville, Louisville, KY 40202, USA.
Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology, San Diego, CA 92037, USA.
出版信息
Pathogens. 2023 Jun 11;12(6):823. doi: 10.3390/pathogens12060823.
Abstract
Among the seven coronaviruses that infect humans, HCoV-229E, HCoV-OC43, HCoV-NL63, and HCoV-HKU1 usually cause mild and common cold symptoms; however, infection with three coronaviruses, namely severe acute respiratory syndrome coronavirus [SARS-CoV], Middle East respiratory syndrome coronavirus [MERS-CoV], and the newly identified severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2], often results in respiratory distress, cytokine storm and multiorgan failure [...].
摘要
在七种感染人类的冠状病毒中，HCoV-229E、HCoV-OC43、HCoV-NL63和HCoV-HKU1通常引起轻微的普通感冒症状；然而，感染三种冠状病毒，即严重急性呼吸综合征冠状病毒[SARS-CoV]、中东呼吸综合征冠状病毒[MERS-CoV]和新发现的严重急性呼吸综合征冠状病毒2[SARS-CoV-2]，常常导致呼吸窘迫、细胞因子风暴和多器官衰竭[...]。
相似文献
1
Broad-Spectrum Antivirals against Multiple Human and Animal Coronaviruses Infection.针对多种人类和动物冠状病毒感染的广谱抗病毒药物。
Pathogens. 2023 Jun 11;12(6):823. doi: 10.3390/pathogens12060823.
2
An overview on the seven pathogenic human coronaviruses.七种人类致病冠状病毒概述。
Rev Med Virol. 2022 Mar;32(2):e2282. doi: 10.1002/rmv.2282. Epub 2021 Aug 2.
3
[SARS, MERS and coronavirus infections].[严重急性呼吸综合征、中东呼吸综合征与冠状病毒感染]
Nihon Rinsho. 2016 Dec;74(12):1967-1972.
4
Severe Acute Respiratory Syndrome Coronavirus 2 Vaccination Boosts Neutralizing Activity Against Seasonal Human Coronaviruses.严重急性呼吸综合征冠状病毒 2 疫苗接种增强了对季节性人类冠状病毒的中和活性。
Clin Infect Dis. 2022 Aug 24;75(1):e653-e661. doi: 10.1093/cid/ciac057.
5
Human and novel coronavirus infections in children: a review.儿童人感染和新型冠状病毒感染：综述。
Paediatr Int Child Health. 2021 Feb;41(1):36-55. doi: 10.1080/20469047.2020.1781356. Epub 2020 Jun 25.
6
Mechanistic insights into SARS-CoV-2 epidemic via revealing the features of SARS-CoV-2 coding proteins and host responses upon its infection.通过揭示 SARS-CoV-2 编码蛋白的特征及其感染宿主后的反应，深入了解 SARS-CoV-2 疫情的发病机制。
Bioinformatics. 2021 Jan 29;36(21):5133-5138. doi: 10.1093/bioinformatics/btaa725.
7
Fully automated detection and differentiation of pandemic and endemic coronaviruses (NL63, 229E, HKU1, OC43 and SARS-CoV-2) on the hologic panther fusion.在 hologic panther fusion 系统上全自动检测和区分大流行冠状病毒和地方性冠状病毒（NL63、229E、HKU1、OC43 和 SARS-CoV-2）。
J Med Virol. 2021 Jul;93(7):4438-4445. doi: 10.1002/jmv.26749.
8
Tracing the SARS-coronavirus.追踪 SARS 冠状病毒。
J Thorac Dis. 2013 Aug;5 Suppl 2(Suppl 2):S118-21. doi: 10.3978/j.issn.2072-1439.2013.06.19.
9
Coronavirus HKU1 and other coronavirus infections in Hong Kong.香港的冠状病毒HKU1及其他冠状病毒感染
J Clin Microbiol. 2006 Jun;44(6):2063-71. doi: 10.1128/JCM.02614-05.
10
Cytopathic Effect Assay and Plaque Assay to Evaluate Activity of Antiviral Compounds Against Human Coronaviruses 229E, OC43, and NL63.细胞病变效应测定和噬斑测定以评估抗病毒化合物对人冠状病毒229E、OC43和NL63的活性
Bio Protoc. 2022 Feb 5;12(3):e4314. doi: 10.21769/BioProtoc.4314.
本文引用的文献
1
Effectiveness of Paxlovid in Reducing Severe Coronavirus Disease 2019 and Mortality in High-Risk Patients.帕克洛维德降低高危患者的严重 2019 冠状病毒病和死亡率的有效性。
Clin Infect Dis. 2023 Feb 8;76(3):e342-e349. doi: 10.1093/cid/ciac443.
2
A Highly Potent SARS-CoV-2 Blocking Lectin Protein.一种高效的 SARS-CoV-2 阻断凝集素蛋白。
ACS Infect Dis. 2022 Jul 8;8(7):1253-1264. doi: 10.1021/acsinfecdis.2c00006. Epub 2022 Apr 15.
3
An Overview of the Pathogenesis, Transmission, Diagnosis, and Management of Endemic Human Coronaviruses: A Reflection on the Past and Present Episodes and Possible Future Outbreaks.地方性人类冠状病毒的发病机制、传播、诊断与管理概述：对过去和当前疫情及未来可能爆发情况的思考
Pathogens. 2021 Aug 30;10(9):1108. doi: 10.3390/pathogens10091108.
4
Phycobilins as Potent Food Bioactive Broad-Spectrum Inhibitors Against Proteases of SARS-CoV-2 and Other Coronaviruses: A Preliminary Study.藻胆素作为针对严重急性呼吸综合征冠状病毒2（SARS-CoV-2）和其他冠状病毒蛋白酶的强效食品生物活性广谱抑制剂：一项初步研究。
Front Microbiol. 2021 Jun 10;12:645713. doi: 10.3389/fmicb.2021.645713. eCollection 2021.
5
HTCC as a Polymeric Inhibitor of SARS-CoV-2 and MERS-CoV.HTCC 作为 SARS-CoV-2 和 MERS-CoV 的聚合抑制剂。
J Virol. 2021 Jan 28;95(4). doi: 10.1128/JVI.01622-20.
6
Clinical benefit of remdesivir in rhesus macaques infected with SARS-CoV-2.瑞德西韦在感染 SARS-CoV-2 的恒河猴中的临床获益。
Nature. 2020 Sep;585(7824):273-276. doi: 10.1038/s41586-020-2423-5. Epub 2020 Jun 9.
7
An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice.一种口服生物利用度的广谱抗病毒药物可抑制人呼吸道上皮细胞培养中的 SARS-CoV-2 病毒和小鼠中的多种冠状病毒。
Sci Transl Med. 2020 Apr 29;12(541). doi: 10.1126/scitranslmed.abb5883. Epub 2020 Apr 6.
8
Insights into the Recent 2019 Novel Coronavirus (SARS-CoV-2) in Light of Past Human Coronavirus Outbreaks.鉴于过去人类冠状病毒爆发情况洞察2019新型冠状病毒（SARS-CoV-2）
Pathogens. 2020 Mar 4;9(3):186. doi: 10.3390/pathogens9030186.
9
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.严重急性呼吸综合征冠状病毒 2 型（SARS-CoV-2）进入细胞依赖于 ACE2 和 TMPRSS2，可被一种临床验证的蛋白酶抑制剂所阻断。
Cell. 2020 Apr 16;181(2):271-280.e8. doi: 10.1016/j.cell.2020.02.052. Epub 2020 Mar 5.
10
A systematic review of lopinavir therapy for SARS coronavirus and MERS coronavirus-A possible reference for coronavirus disease-19 treatment option.洛匹那韦疗法治疗严重急性呼吸综合征冠状病毒和中东呼吸综合征冠状病毒的系统评价——为新型冠状病毒病治疗方案提供参考。
J Med Virol. 2020 Jun;92(6):556-563. doi: 10.1002/jmv.25729. Epub 2020 Mar 12.
Zotero 插件